sfa 24:0

Lignoceric acid (SFA 24:0), also known as tetracosanoic acid, is a very‑long‑chain saturated fatty acid characterized by a straight chain of 24 carbon atoms and no double bonds. Structurally, it belongs to the family of saturated fatty acids (SFAs), which are fatty molecules with only single carbon–carbon bonds. In nutritional biochemistry, individual fatty acids are commonly abbreviated by their carbon length and number of unsaturations, so 24:0 denotes a 24‑carbon chain with zero double bonds. Lignoceric acid is found in nature as a component of complex lipids, particularly sphingolipids and ceramides, which are critical structural lipids in cell membranes, especially within nervous tissue and skin barriers. It is also present in trace amounts in many dietary fats and oils, with the highest relative concentrations typically found in nut and seed oils such as peanut oil and in foods like peanut butter and dry roasted peanuts. Although it is a measurable part of the fatty acid profile in foods, lignoceric acid is not considered an essential nutrient because humans can synthesize the fatty acid de novo through elongation pathways of shorter chain saturated fatty acids. In human metabolism, very‑long‑chain saturated fatty acids like lignoceric acid are metabolized differently than shorter SFAs: they undergo initial breakdown in the peroxisomes before further oxidation in mitochondria. This unique metabolic routing reflects their distinct roles in cell physiology. Because it does not have a designated dietary requirement from federal nutrition authorities, most guidance on lignoceric acid intake falls under broader saturated fat recommendations aimed at supporting cardiovascular health and overall metabolic balance.

Lignoceric acid’s primary biological roles are structural rather than energetic. It is an integral component of sphingolipids, a class of lipids that form essential parts of cell membranes, particularly in the brain and nervous system. Within sphingolipids, lignoceric acid is incorporated into ceramides, which contribute to the integrity of the skin barrier and neural tissues. Because of this incorporation into complex lipids, very‑long‑chain saturated fatty acids are crucial for maintaining membrane stability and fluidity in specific tissues. Although standard dietary guidance does not highlight SFA 24:0 as a target nutrient, emerging research has investigated associations between circulating levels of very‑long‑chain saturated fatty acids and health outcomes. For example, a recent cohort study of older adults found that higher circulating levels of lignoceric acid and related long chain SFAs were associated with better global cognitive function and lower risk of unhealthy aging events, suggesting potential links between these fatty acids and age‑related health measures. Specifically, in the National Health and Nutrition Examination Survey (NHANES) analysis, circulating 24:0 was positively associated with cognitive test performance in adults aged 60 and over. In addition, higher plasma levels of very long chain SFAs have been linked observationally with lower risks of diabetes mellitus, heart failure, and certain cardiovascular conditions in some epidemiologic studies. Mechanistically, these associations may reflect complex interactions between lipid metabolism, inflammation, and membrane composition, although causality is not established. It is important to interpret these findings cautiously: current evidence does not support recommending increased intake of any specific saturated fatty acid, including lignoceric acid, as a health intervention. The broader body of research on saturated fats indicates that high total intake can adversely affect serum LDL‑cholesterol levels, a risk factor for atherosclerotic cardiovascular disease. Therefore, while circulating levels of lignoceric acid may have biomarker associations with health in research settings, public health guidance continues to emphasize limiting total saturated fat intake and replacing some SFAs with unsaturated fats to support cardiovascular health.

Unlike essential nutrients such as vitamins and minerals, there are no established Recommended Dietary Allowances (RDAs) or Adequate Intakes (AIs) for individual fatty acids like lignoceric acid. The U.S. Dietary Guidelines recommend that total saturated fat intake (which includes all individual SFAs such as palmitic, stearic, and lignoceric acids) should constitute less than 10% of daily energy to support cardiovascular health in the general population. This <10% recommendation is a population‑level guideline aimed at reducing the risk of elevated LDL‑cholesterol and associated atherosclerotic disease. Because lignoceric acid comprises only a small fraction of total dietary saturated fats, no specific intake target for 24:0 exists. In clinical nutrition, total fat intake (including saturated, monounsaturated, and polyunsaturated fats) is considered within the context of overall energy balance, dietary pattern, and individual health status. For people with dyslipidemia or elevated cardiovascular risk, many clinicians recommend even lower saturated fat targets and emphasize replacing SFAs with monounsaturated and polyunsaturated fats to improve lipid profiles. Factors influencing how much SFA 24:0 appears in circulation include both dietary sources and endogenous metabolic pathways; the body synthesizes some very‑long‑chain fatty acids from shorter chain precursors via elongase enzymes. Given the lack of specific dietary requirements for lignoceric acid itself, guidance focuses on the quality and balance of fats in the diet rather than isolating intake of C24:0. For individuals seeking to understand their fatty acid profiles—for example, through advanced lipid testing or research studies—target ranges are emerging in the scientific literature, but these are not recognized as clinical reference values by major nutrition authorities. In summary, intake of lignoceric acid should be considered within the broader context of total saturated fat consumption, with attention to overall dietary fat quality and health goals.

Because lignoceric acid is not an essential nutrient—meaning the human body can synthesize it from shorter chain fatty acids—there are no deficiency diseases linked exclusively to inadequate intake of 24:0. In contrast to essential fatty acids like alpha‑linolenic acid and linoleic acid, which have established deficiency syndromes, very‑long‑chain saturated fatty acids such as C24:0 are incorporated into body lipids as needed. Therefore, clinical deficiency symptoms attributable solely to low dietary lignoceric acid have not been documented. Observationally, very low circulating levels of VLCFAs including lignoceric acid might appear in disorders of peroxisomal metabolism, such as Zellweger spectrum disorders and X‑linked adrenoleukodystrophy, where defective peroxisomal oxidation leads to abnormal accumulation rather than deficiency. These rare genetic conditions highlight the role of peroxisomal pathways in VLCFA metabolism rather than dietary insufficiency. Clinically, symptoms in peroxisomal disorders include neurological dysfunction, hepatomegaly, and developmental delays, but these are driven by metabolic derangements and accumulation of VLCFAs rather than lack of dietary intake. In healthy populations, there is no research establishing specific signs or symptoms that would reliably indicate insufficient intake of lignoceric acid. Any observed low levels in plasma phospholipid fatty acid analysis are generally interpreted in the context of overall fat consumption patterns and metabolic status rather than isolated deficiency. Consequently, clinicians do not screen for or diagnose deficiency of lignoceric acid per se.

Because lignoceric acid is a minor component of dietary fats, it appears in foods that contain saturated fats, particularly certain nuts, oils, and processed foods. Data from nutrient composition databases show that the highest amounts of 24:0 per typical serving are found in products such as peanut butter, dry roasted peanuts, peanut oil, and some nut oils. Other sources with lower but measurable amounts include macadamia nuts, flaxseed oil, and various seeds. Many processed foods and fast foods contain trace amounts reflecting their fat content. Given that 24:0 constitutes a small percentage of total fats, the absolute amounts per serving tend to be modest. Nonetheless, for illustrative purposes, the following foods contain measurable lignoceric acid when analyzed through standard food composition data: peanut butter and peanuts, peanut oil, dry roasted mixed nuts, macadamia nuts, flaxseed oil, sesame seeds, and sunflower seeds. Typical serving sizes deliver amounts in the range of tens to hundreds of milligrams. It is important to note that while these foods contribute lignoceric acid, they also contribute other saturated fats and calories; thus, intake should be balanced within the context of total fat and energy goals. Consuming a variety of nuts, seeds, and plant oils in moderation can provide very‑long‑chain saturated fatty acids alongside beneficial unsaturated fats, fiber, vitamins, and minerals. Compared to animal sources of saturated fat such as butter and fatty meats, nut and seed sources often offer more favorable lipid profiles, although total saturated fat considerations remain relevant. Including a mix of foods high in unsaturated fats—such as olive oil, avocados, and fatty fish—while limiting excess saturated fats aligns with dietary patterns recommended by major health organizations to support cardiovascular and metabolic health.

Like other dietary fats, lignoceric acid is absorbed in the small intestine after being incorporated into mixed micelles with the aid of bile salts. Pancreatic lipases hydrolyze triglycerides to release free fatty acids and monoglycerides, which are then taken up by enterocytes largely through passive diffusion. Within enterocytes, free fatty acids including C24:0 are re‑esterified into triglycerides and packaged into chylomicrons for lymphatic transport into the bloodstream. Because lignoceric acid is a saturated fatty acid with a long carbon chain, its incorporation into complex lipids and metabolism differs somewhat from shorter chain fatty acids. Very‑long‑chain saturated fatty acids like lignoceric acid are preferentially metabolized in peroxisomes via beta‑oxidation, a distinctive pathway compared to the mitochondrial beta‑oxidation of medium and long chain fatty acids. This metabolic processing influences how these fatty acids are utilized for energy and structural functions within cells. Bioavailability of lignoceric acid from food is generally high given that it is incorporated into dietary fats; however, because it constitutes a small fraction of total dietary fat, its specific bioavailability has not been extensively quantified in clinical studies. Absorption can be influenced by overall fat digestion efficiency, presence of bile salts, and intestinal health. Concurrent intake of other fats, fiber, and nutrients can affect micelle formation and fat absorption, with high fiber sometimes reducing overall fat absorption. In summary, 24:0 follows the typical pathways of long‑chain fatty acid absorption and metabolism, with unique aspects in its subsequent cellular processing due to its very long chain length.

Unlike essential fatty acids (such as omega‑3 and omega‑6), lignoceric acid is not recognized as an essential nutrient and does not have established dietary intake recommendations or deficiency syndromes. Consequently, there are no mainstream dietary supplements formulated specifically to provide lignoceric acid for general health. Some specialized products may include very‑long‑chain fatty acids or ceramide precursors in topical skincare formulations aimed at supporting skin barrier function, but these are not dietary supplements intended for systemic health. Because lignoceric acid constitutes only a small portion of dietary fats and the body can synthesize it endogenously, supplemental intake is not necessary under normal conditions. For individuals with concerns about fatty acid metabolism or specific metabolic disorders, any consideration of supplements should be guided by a healthcare provider. Overall, evidence supporting health benefits from taking isolated lignoceric acid supplements is lacking; dietary and health guidance focuses instead on balanced fat intake and meeting essential nutrient needs.

There are no established tolerable upper intake levels (ULs) for lignoceric acid specifically because it is a minor component of saturated fat and not considered an essential nutrient with toxicity thresholds. However, excessive intake of total saturated fat—which includes lignoceric acid along with other SFAs—has been consistently linked in research to elevated LDL‑cholesterol levels and increased risk of atherosclerotic cardiovascular disease. Therefore, public health guidelines recommend limiting total saturated fat intake to less than 10% of daily calories. Consistently consuming high amounts of saturated fats can adversely affect lipid profiles and cardiovascular risk factors, reinforcing the importance of moderation in overall saturated fat consumption rather than focusing on individual components like 24:0.

Lignoceric acid itself does not have well‑documented direct interactions with medications, largely because it is not used therapeutically and does not have specific supplemental forms. However, patterns of saturated fat intake can influence how certain lipid‑lowering medications perform. For example, diets high in saturated fats can blunt the cholesterol‑lowering effects of statins such as atorvastatin and simvastatin by sustaining high LDL‑cholesterol levels, making pharmacologic lipid management less effective. Therefore, individuals taking lipid‑lowering drugs are advised to adhere to dietary patterns low in saturated fats to maximize therapeutic benefit. Additionally, high saturated fat intake may interact with bile acid sequestrants such as cholestyramine by influencing bile acid metabolism and fat absorption, potentially affecting fat‑soluble vitamin absorption. In summary, while 24:0 itself does not interact pharmacologically, its contribution to total saturated fat intake can modulate the context in which lipid‑modifying drugs work.